바이옴 홀딩스(HIND)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.10 (+7.14%), 시가총액 $13.48M, 52주 범위 $1.88 ~ $14.00.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne.
바이옴 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
바이옴 홀딩스의 현재 주가는 $2.10 (+7.14%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
바이옴 홀딩스의 시가총액은 약 $13.48M입니다.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States.